A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

UK denies approval for Genmab's Darzalex combo

British authorities withhold support for Genmab and partner Johnson & Johnson's bid to expand the indication for cancer medication Darzalex, reports Pharmatimes.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Genmab and partner Johnson & Johnson will not support the extension of the user application of cancer treatment Darzalex, shows a document draft from the UK National Institute for Health and Clinical Excellence (NICE), which advises England and Wales on medications, reports sector media Pharmatimes.

In the document, NICE grounds its conclusion citing concerns about the long-term effect of using Darzalex in combination with Velcade, Thalidomid and Dexamethason as first-line treatments for bone marrow cancer with patients well suited for stem cell transplantation.

Today, patients are typically treated with the same cocktail of drugs excluding Darzalex. NICE also bases its decision on concerns of cost relative to effect, Pharmatimes writes.

European heath authorities issued approval for Darzalex in the aforementioned combination back in 2020 as an initial treatment of patients for whom stem cell transplantation is deemed appropriate.

Genmab: Janssen dispute cost DKK 146m in H1

Genmab's successful CEO dismisses retirement plans  

Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures 

 

Share article

Related articles:

  • Photo: Tuala Hjarnø / Genmab / PR

    Genmab: Janssen dispute cost DKK 146m in H1

    For subscribers

  • Photo: PR / Genmab

    Genmab's successful CEO dismisses retirement plans

    For subscribers

  • Photo: Joost Melis / Genmab / PR

    Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers



Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Photo: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Foto: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


  • Foto: Tom Little

    Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

    The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

    For subscribers


  • Foto: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Foto: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


Further reading

Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers


Foto: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers



Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Discovery Project Leader, Principal Scientist

  • QA/RA Manager

  • Global Medical Manager

  • Project Director, HR & ESG

  • Senior Legal Councel

  • Qualified Person to AJ Vaccines

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • VP of Software Development, Perfusion Tech

  • Senior QA Specialists (GMP or GCP)

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Director, Head of Antibody Technology

  • Chemist for Incoming Materials in QC department

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Discovery Project Leader, Principal Scientist

  • QA/RA Manager

  • Global Medical Manager

  • Project Director, HR & ESG

  • Senior Legal Councel

  • Qualified Person to AJ Vaccines

  • Audit & Supplier Manager

  • Clinical Supply Manager

  • VP of Software Development, Perfusion Tech

  • Senior QA Specialists (GMP or GCP)

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Director, Head of Antibody Technology

  • Chemist for Incoming Materials in QC department

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved